Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tyra BiosciencesTYRA -6.41%33 Cash-to-Debt is 63.41 as of Jun. 2026, which is 8% above its 10-year median of 58.96. GuruFocus rates TYRA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, Tyra Biosciences ranks better than 73.07% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tyra Biosciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 63.41.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tyra Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Tyra Biosciences's Cash-to-Debt or its related term are showing as below:
TYRA'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43 Med: 58.96 Max: 266.91
Current: 63.41
During the past 7 years, Tyra Biosciences's highest Cash to Debt Ratio was 266.91. The lowest was 0.43. And the median was 58.96.
TYRA's Cash-to-Debt is ranked better than 73.07% of 1396
companies
in the Biotechnology industry
Industry Median: 7.175
vs TYRA: 63.41
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Tyra Biosciences Cash-to-Debt Related Terms
Tyra Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Tyra Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Tyra Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tyra Biosciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Tyra Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tyra Biosciences (TYRA) has a Cash-to-Debt of 63.41 as of Jun. 2026. This is near median its historical median of 58.96. Over the past decade, Tyra Biosciences' Cash-to-Debt has ranged from 0.43 to 266.91. According to the industry distribution chart, Tyra Biosciences ranks #376 out of 1396 companies in the Biotechnology industry, placing it in the top 26.9%.
Is Tyra Biosciences' Cash-to-Debt too high?
Tyra Biosciences' current Cash-to-Debt of 63.41 is near median its 10-year median of 58.96. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 266.91. The Biotechnology industry median Cash-to-Debt is 7.18. Tyra Biosciences' value of 63.41 is 783.8% above this industry median. Based on the distribution chart, Tyra Biosciences ranks #376 out of 1396 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tyra Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Cash-to-Debt compare to AVBP and TRAX?
According to the Biotechnology industry distribution chart, Tyra Biosciences ranks #376 out of 1396 companies for Cash-to-Debt. This puts Tyra Biosciences in the upper half of its industry. The industry median Cash-to-Debt is 7.18. Tyra Biosciences' value of 63.41 is 783.8% above this benchmark. Historically, Tyra Biosciences' own Cash-to-Debt has ranged from 0.43 to 266.91 over the past decade. While the company's 10-year median is 58.96 vs. the industry median of 7.18, Tyra Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.18, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tyra Biosciences's current Cash-to-Debt of 63.41 is 783.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tyra Biosciences's current Cash-to-Debt is 63.41, which is near median its own 10-year median of 58.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Cash-to-Debt of 63.41. The current Cash-to-Debt is 63.41, which is near median its 10-year median of 58.96 and 783.8% above the Biotechnology industry median of 7.18. Tyra Biosciences' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Cash-to-Debt is 63.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
33GF Score
Get the complete analysis for TYRA
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYRA has been successfully added to your 
